Quincey James, chairman of both Coca-Cola (KO) and Pfizer (PFE), has filed 37 Form 4 transactions across the two companies, with a pronounced sell-side bias. Over the reporting period, James recorded zero open-market purchases and roughly $170.1 million in total sales, nearly all of it in KO shares. The selling has been steady and substantial: on July 29, 2026, he sold $13.1 million worth of KO; the prior day, $34.3 million; on June 5, $35.0 million; and on March 3, $19.8 million. These open-market sales were frequently paired with option exercises (code M) of similar or slightly smaller value—for instance, a $34.3 million sale on July 28 accompanied a $17.3 million exercise—suggesting a pattern of monetizing vested equity rather than accumulating new exposure.
The only other activity in KO has been mechanical or non-discretionary: a $12.0 million tax-withholding event (code F) on February 27, 2026, and two zero-value grants (code A) later that month. A gift of zero value on May 11, 2026, rounds out the non-sale transactions. In PFE, James’s filings are entirely compensation-driven: a series of small awards (code A) ranging from $38,750 to $205,000, dated quarterly from September 2025 through June 2026, with no corresponding sales. The total acquired value across both tickers—$631,250—is dwarfed by the sell volume, and the eight most recent trades (all in KO) were sales or option exercises, with no buys in the last year.
The pattern is unambiguous: James is a consistent, high-volume seller of KO stock, using option exercises to facilitate liquidity, while his PFE holdings are passive accumulations of restricted stock. His recent direction—eight straight sell-side filings in KO through late July 2026—shows no reversal of that trend.
AI-assisted summary